Veneris JT - Search Results

1

Using MKK4's metastasis suppressor function to identify and dissect cancer cell-microenvironment interactions during metastatic colonization.

Krishnan V, Stadick N, Clark R, Bainer R, Veneris JT, Khan S, Drew A, Rinker-Schaeffer C. Krishnan V, et al. Among authors: veneris jt. Cancer Metastasis Rev. 2012 Dec;31(3-4):605-13. doi: 10.1007/s10555-012-9371-y. Cancer Metastasis Rev. 2012. PMID: 22706843 Review.

2

Time-dependent transcriptional profiling links gene expression to mitogen-activated protein kinase kinase 4 (MKK4)-mediated suppression of omental metastatic colonization.

Bainer RO, Veneris JT, Yamada SD, Montag A, Lingen MW, Gilad Y, Rinker-Schaeffer CW. Bainer RO, et al. Among authors: veneris jt. Clin Exp Metastasis. 2012 Jun;29(5):397-408. doi: 10.1007/s10585-011-9448-y. Epub 2012 Feb 21. Clin Exp Metastasis. 2012. PMID: 22350525 Free PMC article.

3

Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.

Tangen IL, Veneris JT, Halle MK, Werner HM, Trovik J, Akslen LA, Salvesen HB, Conzen SD, Fleming GF, Krakstad C. Tangen IL, et al. Among authors: veneris jt. Gynecol Oncol. 2017 Dec;147(3):672-677. doi: 10.1016/j.ygyno.2017.09.013. Epub 2017 Sep 18. Gynecol Oncol. 2017. PMID: 28927900

4

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, Oaknin A, Hamilton E, Wang Y, Sarkar I, Molinero L, Fassò M, O'Hear C, Lin YG, Emens LA. Liu JF, et al. Gynecol Oncol. 2019 Aug;154(2):314-322. doi: 10.1016/j.ygyno.2019.05.021. Epub 2019 Jun 14. Gynecol Oncol. 2019. PMID: 31204078 Clinical Trial.

5

High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer.

Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. Veneris JT, et al. Gynecol Oncol. 2017 Jul;146(1):153-160. doi: 10.1016/j.ygyno.2017.04.012. Epub 2017 Apr 26. Gynecol Oncol. 2017. PMID: 28456378 Free PMC article.

6

Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer.

Veneris JT, Huang L, Churpek JE, Conzen SD, Fleming GF. Veneris JT, et al. Int J Gynecol Cancer. 2019 Feb;29(2):357-364. doi: 10.1136/ijgc-2018-000101. Epub 2019 Jan 25. Int J Gynecol Cancer. 2019. PMID: 30683758

7

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma.

Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, West G, Quinn R, Matulonis UA, Konstantinopoulos PA. Liu JF, et al. J Clin Oncol. 2021 May 10;39(14):1531-1539. doi: 10.1200/JCO.20.03167. Epub 2021 Mar 11. J Clin Oncol. 2021. PMID: 33705205 Clinical Trial.

8

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.

Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA. Veneris JT, et al. Gynecol Oncol. 2020 Feb;156(2):488-497. doi: 10.1016/j.ygyno.2019.09.021. Epub 2019 Oct 17. Gynecol Oncol. 2020. PMID: 31630846 Free article. Review.

9

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.

Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Oaknin A, et al. J Immunother Cancer. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777. J Immunother Cancer. 2022. PMID: 35064011 Free PMC article. Clinical Trial.

10

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S. Veneris JT, et al. Gynecol Oncol. 2019 Jun;153(3):471-478. doi: 10.1016/j.ygyno.2019.03.247. Epub 2019 Mar 29. Gynecol Oncol. 2019. PMID: 30935717

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters